Vivek Subbiah, MD

Thanks @eaonc for highlighting the important mission to serve patients via innovative transformative research! Supporting research improves outcomes & saves lives! @Dr_AmerZeidan @VivekSubbiah @LeiDeng3 @DrOmarMian @spsutkaMD @montypal @mshadman @fredhutch @DimaDanai @FaltasLab

Nardo et al: "Pembrolizumab in patients with advanced miscellaneous rare cancers: Results from a phase 2 basket trial" doi.org/10.36401/JIPO-… #precisiononcology #immunotherapy #raretumors #JIPO @mirella_nardo @CamilaBraganca @VivekSubbiah X @DavidHongMD @ANaingMD

✍️ Writing is thinking. 👉🏼A powerful editorial in Nature Reviews Bioengineering (Vol. 3, p. 431, 2025) reminds us of something timeless: in science, writing is far more than reporting results. It’s a way of sharpening thought. 👉🏼Even in an age shaped by large-language models,…

Cancer treatment paradigms in the precision medicine era ⁦@NatureMedicine⁩ nature.com/articles/s4159…

🌕 On July 20, humanity reached the moon. Today on #NationalMoonDay, we celebrate the historic moon landing, honoring the astronauts' bravery, engineers' ingenuity, and the groundbreaking technology that enabled this achievement. Today, we reach deeper into cancer’s molecular…

Interpreting Changes to Lung Adenocarcinoma Prognosis over Two Decades | NEJM Evidence evidence.nejm.org/doi/full/10.10…

⭐️Mitochondrial Donation and Preimplantation Genetic Testing for mtDNA Disease | New England Journal of Medicine nejm.org/doi/full/10.10…

Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models: Cancer Cell cell.com/cancer-cell/fu…

Estimates and Projections of the Global Economic Cost of 29 Cancers From 2020 to 2050 jamanetwork.com/journals/jamao…

A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid Tumors jamanetwork.com/journals/jamao…

Undruggable ‘disordered’ proteins become druggable with new AI techniques from David Baker statnews.com/2025/07/17/nob… via @statnews

⭐️Bridging tumour classification and treatment @TheLancetOncol thelancet.com/journals/lanon…

#KCRS25 Excellent opening session on non clear cell RCC: arguments/fallacies, rational patient selection, trial designs, regulatory guidance — coalescing around a collaborative framework, ⬇️ barriers, ⬆️ equity @DrChoueiri @HHammersMD @DrRanaMcKay @arihakimi @kidneycan

#KCRS25 Our second pre-meeting session explored how to design and run better clinical trials for rare kidney cancer subtypes: Lessons from Other Cancers with @VivekSubbiah Statistical Design Strategies with Wanling Xie Regulatory Pathways & Endpoints with @chana_weinstock…

Brilliant tumor-agnostic trial insights by @VivekSubbiah at #KCRS25: ✅ Every target is pan-target ✅ No “undruggable” targets ✅ Patients can’t wait! We can fine-tune later, but we must start now. @kidneycan @IKCCorg @advocatekidneys @DrChoueiri @HHammersMD @OncoAlert @montypal…

Every waterfall plot, every CT scan, there’s a patient, a family, a life behind it. Thank you @VivekSubbiah for the reminder at #KCRS25 @kidneycan @IKCCorg @advocatekidneys @DrChoueiri @HHammersMD @OncoAlert @montypal @NazliDizman @yekeduz_emre @AlbigesL @MikeSerzanMD @arihakimi…

✅ Success is possible even in rare cancer subtypes 🌟 🤝 Patient-centered care 🗣️ Advocacy @KidneyCAN 🧬 Tissue-agnostic biomarkers 🧪 Innovative trial designs 🏭 Industry support 📊 Prospective randomized phase 3 data wherever possible Great panel at #KCRS25 with optimism…

Join us #KCRS2025 —unmissable how to design and excite from other trials and bring them into kidney cancer —⁦@kidneycan⁩ ⁦@VivekSubbiah⁩ ⁦@montypal⁩